1.825

2.81% 0.045

Inovio Pharmaceuticals Inc (INO)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$1.78

Offen:

$1.8

24-Stunden-Volumen:

400.88K

Relative Volume:

0.57

Marktkapitalisierung:

$64.55M

Einnahmen:

$832.00K

Nettoeinkommen (Verlust:

$-135.12M

KGV:

-0.2997

EPS:

-6.09

Netto-Cashflow:

$-124.69M

1W Leistung:

+3.98%

1M Leistung:

-4.69%

6M Leistung:

-67.89%

1J Leistung:

-81.74%

1-Tages-Spanne:

$1.78

$1.86

1-Wochen-Bereich:

$1.675

$1.9192

52-Wochen-Spanne:

$1.42

$13.44

Inovio Pharmaceuticals Inc Stock (INO) Company Profile

Firmenname

Inovio Pharmaceuticals Inc

Sektor

Healthcare (1155)

Branche

Biotechnology (677)

Telefon

(858) 410-3134

Adresse

660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA

Mitarbeiter

134

Twitter

@inoviopharma

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

INO's Discussions on Twitter

Vergleichen Sie INO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
INO Inovio Pharmaceuticals Inc	1.835	64.55M	832.00K	-135.12M	-124.69M	-6.09
VRTX Vertex Pharmaceuticals Inc	489.30	128.67B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	583.10	60.99B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	599.94	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	235.79	29.89B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	253.84	26.16B	3.81B	-644.79M	-669.77M	-6.24

Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-05-14	Eingeleitet	Stephens	Overweight
2024-01-25	Hochstufung	Oppenheimer	Perform → Outperform
2022-11-09	Herabstufung	Maxim Group	Buy → Hold
2022-11-01	Herabstufung	BofA Securities	Neutral → Underperform
2022-07-19	Fortgesetzt	RBC Capital Mkts	Sector Perform
2022-05-11	Herabstufung	Oppenheimer	Outperform → Perform
2022-01-21	Hochstufung	BofA Securities	Underperform → Neutral
2021-12-29	Fortgesetzt	Jefferies	Hold
2021-09-10	Herabstufung	BofA Securities	Neutral → Underperform
2021-06-24	Eingeleitet	Jefferies	Hold
2021-03-23	Eingeleitet	BofA Securities	Neutral
2021-02-12	Eingeleitet	Oppenheimer	Outperform
2020-11-17	Herabstufung	ROTH Capital	Neutral → Sell
2020-11-10	Hochstufung	ROTH Capital	Sell → Neutral
2020-09-28	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2020-09-28	Hochstufung	Maxim Group	Hold → Buy
2020-07-01	Herabstufung	Maxim Group	Buy → Hold
2020-07-01	Herabstufung	ROTH Capital	Neutral → Sell
2020-06-29	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-06-26	Herabstufung	Stifel	Buy → Hold
2020-05-21	Eingeleitet	The Benchmark Company	Buy
2020-04-30	Herabstufung	ROTH Capital	Buy → Neutral
2020-03-13	Herabstufung	Piper Sandler	Overweight → Neutral
2020-03-13	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2019-12-19	Eingeleitet	ROTH Capital	Buy
2018-02-15	Bestätigt	Maxim Group	Buy
2017-10-18	Eingeleitet	RBC Capital Mkts	Outperform
2017-09-06	Eingeleitet	Citigroup	Buy
2017-06-08	Hochstufung	Piper Jaffray	Neutral → Overweight
2017-05-24	Bestätigt	Maxim Group	Buy
2017-03-16	Hochstufung	Maxim Group	Hold → Buy
2017-03-16	Herabstufung	Piper Jaffray	Overweight → Neutral

Alle ansehen

Inovio Pharmaceuticals Inc Aktie (INO) Neueste Nachrichten

Apr 21, 2025

Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Apr 21, 2025

Bet on These 5 Top-Ranked Stocks With Rising P/E - Yahoo Finance

Apr 21, 2025

Apr 17, 2025

Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial - ADVFN

Apr 17, 2025

Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch

Apr 17, 2025

Apr 16, 2025

Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Apr 16, 2025

Apr 11, 2025

Inovio Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch

Apr 11, 2025

INOVIO to Highlight Breakthrough Immunotherapy Data at AACR Conference - MSN

Apr 11, 2025

INOVIO to Showcase Breakthrough Data on INO-3107 at Major Industry Conferences - MyChesCo

Apr 11, 2025

Apr 10, 2025

Inovio Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch

Apr 09, 2025

INOVIO to Present at Upcoming Scientific Conferences | INO Stock News - GuruFocus

Apr 09, 2025

INOVIO to Present at Upcoming Scientific Conferences - Longview News-Journal

Apr 09, 2025

INOVIO's Breakthrough: 72% Success in HPV TreatmentMultiple Conference Spotlights - Stock Titan

Apr 09, 2025

Apr 08, 2025

Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Apr 08, 2025

Apr 07, 2025

Inovio stock touches 52-week low at $1.47 amid market challenges By Investing.com - Investing.com South Africa

Apr 07, 2025

Inovio stock touches 52-week low at $1.47 amid market challenges - Investing.com Australia

Apr 07, 2025

Apr 04, 2025

Inovio Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch

Apr 04, 2025

Inovio Pharmaceuticals to Host Third Quarter 2013 Earnings Webcast Live on Tuesday, November 12, 2013 - ACCESS Newswire

Apr 04, 2025

Apr 02, 2025

HPV Market to Reach $10.8 Bn, Globally, by 2031 at 12.4% CAGR | - openPR.com

Apr 02, 2025

Apr 01, 2025

Down -11.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO) - Yahoo Finance

Apr 01, 2025

Mar 31, 2025

Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch

Mar 31, 2025

Sector Update: Health Care - MarketScreener

Mar 31, 2025

Mar 28, 2025

Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch

Mar 28, 2025

Mar 26, 2025

Inovio stock plunges to 52-week low at $1.74 amid market challenges By Investing.com - Investing.com South Africa

Mar 26, 2025

Inovio stock plunges to 52-week low at $1.74 amid market challenges - Investing.com Australia

Mar 26, 2025

Mar 25, 2025

Lassa Fever Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Inovio Pharma - Barchart.com

Mar 25, 2025

Mar 22, 2025

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 22, 2025

Mar 21, 2025

INOVIO Reports Progress on INO-3107 and DNA Medicine, 2024 Financial Outcomes - MSN

Mar 21, 2025

Mar 20, 2025

Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Mar 20, 2025

Inovio’s SWOT analysis: dna firm’s stock faces crucial year ahead By Investing.com - Investing.com South Africa

Mar 20, 2025

DNA Vaccines Market and Their Impact on Global Health: Trends & - openPR.com

Mar 20, 2025

Mar 19, 2025

Inovio’s SWOT analysis: dna firm’s stock faces crucial year ahead - Investing.com

Mar 19, 2025

Inovio taking on Covid-19 again, almost 3 years after abandoning vaccine effort - Philadelphia Business Journal

Mar 19, 2025

Inovio aims for INO-3107 regulatory submission by mid-2025 while addressing key manufacturing issues - MSN

Mar 19, 2025

RBC Cuts Price Target on Inovio Pharmaceuticals to $5 From $6, Keeps Sector Perform, Speculative Risk - Marketscreener.com

Mar 19, 2025